key: cord-0970878-hofzsgkh
authors: Meister, Toni Luise; Todt, Daniel; Brüggemann, Yannick; Steinmann, Joerg; Banava, Sepideh; Brill, Florian.H.H.; Steinmann, Jochen; Pfaender, Stephanie; Steinmann, Eike
title: Virucidal Activity of Nasal Sprays Against Severe Acute Respiratory Syndrome Coronavirus 2
date: 2021-11-06
journal: J Hosp Infect
DOI: 10.1016/j.jhin.2021.10.019
sha: cb6f1c28bad2b030749053175c0bac6b4f1dae7f
doc_id: 970878
cord_uid: hofzsgkh

The highest viral loads of the newly emerged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) are detectable in the oral cavity, thus, a potential reduction of infectious virus by nasal sprays could lower transmission. Therefore, the inactivation capacity of nine nasal and oral sprays was evaluated according to EN 14476. One nasal spray based on sodium hypochlorite and an oral spray containing essential oils reduced viral titres between 2 to 3 orders of magnitude. Although clinical data is still sparse, nasal and oral sprays display a more convenient application for elderly people or those who are unable to rinse/gargle.

The highest viral loads of the newly emerged Severe Acute Respiratory Syndrome 25

Coronavirus 2 (SARS-CoV-2) are detectable in the oral cavity, thus, a potential 26 reduction of infectious virus by nasal sprays could lower transmission. Therefore, the 27 inactivation capacity of nine nasal and oral sprays was evaluated according to EN 28 14476. One nasal spray based on sodium hypochlorite and an oral spray containing 29 essential oils reduced viral titres between 2 to 3 orders of magnitude. Although clinical 30 data is still sparse, nasal and oral sprays display a more convenient application for 31 elderly people or those who are unable to rinse/gargle. 32

The newly emerged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-39 2), causing Coronavirus Disease 2019 (COVID-19), represents a major health burden 40 by infecting millions of people worldwide. Although vaccination programs have been 41 successfully implemented in many countries, specific therapies have not been 42 approved yet. Furthermore, the emergence of different variants of concern displaying 43 increased transmissibility, more severe disease, and significant reduction in 44 neutralization by antibodies can reduce the effectiveness of treatments or vaccines 45 increasing cases in the community and more importantly among healthcare workers. 46

Hence, social distancing, personal hygiene measures including frequent hand washing, 47 and wearing face masks remain essential to reduce virus transmission mainly occurring 48 via respiratory secretions. Since the highest viral loads are detectable in the oral cavity, 49 a reduction of infectious virus in the nasopharynx and oropharynx could lower viral 50 shedding and consequently transmission by infected individuals [1] . Recent findings 51 demonstrated the potential of commercially available oral rinses to inactivate SARS-52

CoV-2 in vitro, [2] . In dentistry pre-procedural rinse is a well-established method to 53 reduce microbial pathogens and, although clinical data is sparse, their application was 54 also suggested during the ongoing SARS-CoV-2 pandemic in Germany [3]. The 55 underlying mechanism of virus inactivation is believed to be the sensitivity of the viral 56 envelope towards chemical agents such as ethanol, chlorhexidine, cetylpyridinium 57 chloride, hydrogen peroxide, and povidone-iodine, present in both disinfectants and 58 oral rinses [4] . Depending on their composition, nasal sprays could display similar 59 antiviral properties. The application of oral rinses and nasal sprays that inactivate 60 SARS-CoV-2 could become particularly important when it comes to dental practice, as 61 the aerosol and droplet spread during dental procedures is inevitable and keeping the 62 appropriate distance is impossible. Thus, utilising oral rinses and nasal sprays could 63 possibly reduce the risk of exposure of healthcare workers with infectious virus and cross-contamination between patients. The aim of this study was to assess the capacity 65 of seven different nasal sprays and two oral sprays to inactivate SARS-CoV-2 in vitro. 66

Virucidal activity of seven different nasal sprays and two oral sprays was assessed as 69 acids, 100 IU/mL penicillin, 100 µg/mL streptomycin and 2 mM L-Glutamine). 76

Subsequently, the cells were stained with crystal violet and the 50% tissue culture 77 infective dose (TCID50/mL) was determined. Determination of virucidal activity was 78 calculated by the difference between the medium control and the test product. 79

Cytotoxicity of the different products was evaluated using noninfected cells and set as 80 the lower limit of quantification (LLOQ). 81

In case of product I large volume plating was performed to reduce cell toxicity and 83 reach a ≥4 log10 reduction of viral loads. Thus, similar to the quantitative suspension 84 test, eight parts of product I were combined with one part interfering substance and one 85 part virus. After 30 seconds of incubation, the mixture was diluted 1:1,000 in medium 86 and added to VeroE6 cells plated on six 96 well plates. Medium served as a control. We investigated the virucidal capacity of different commercially available nasal and oral 92 sprays (Table 1) using a quantitative suspension test adapted to European Guideline 93 EN 14476. One-part virus was incubated with one-part interfering substance mimicking 94 nasal secretion and eight parts nasal or oral sprays for 30 seconds ( Figure 1A) . The 95 residual infectious titre was determined by an end-point dilution assay (white bar) and 96 compared to medium treated virus as control (grey bar). Only a nasal spray based on 97 sodium hypochlorite lowered viral titres by 2.21 log10 TCID50/mL ( Figure 1B, Product D) , 98

whereas all other nasal sprays, based on sodium chlorite, xylometazolin hydrochloride 99 or homeopathic remedies, did not affect SARS-CoV-2 infectivity. In line with this notion, 100 an oral spray containing homeopathic remedies also had no impact on infectious viral 101 loads, while an oral spray based on essential oils reduced viral loads to the lower limit 102 of detection ( Figure 1C , Product I). When performing large volume plating with product 103 I, a reduction factor of ≥4.69 log10 TCID50/mL was observed (Table 1) . Taken together, 104 the majority of nasal and oral sprays did not inactivate SARS-CoV-2 within 30 seconds. The application of oral rinses, nasal or oral sprays could potentially reduce infectious 108 viral loads in the oral cavity, thus temporarily lowering the risk of transmission. 109

Depending on the formulation, oral rinses can impede SARS-CoV-2 infectivity in vitro 110 

Is the oral cavity relevant in SARS-CoV-2 pandemic?

Virucidal gargling and 182 virucidal nasal spray

Umgang mit zahnmedizinischen

Oral Rinses Targeting the Viral Lipid Envelope in SARS-CoV-2 Infection

Different Oral Rinses Against Severe Acute Respiratory Syndrome Coronavirus 2

Comparable 194 environmental stability and disinfection profiles of the currently circulating SARS-CoV-2 variants 195 of concern B.1.1.7 and B.1.351

Chlorine Dioxide and Sodium Hypochlorite against Feline Calicivirus, Human Influenza Virus

Human Adenovirus, Canine 199 Adenovirus and Canine Parvovirus

Carrageenan-containing over-202 the-counter nasal and oral sprays inhibit SARS-CoV-2 infection of airway epithelial cultures

Iota-carrageenan 206 neutralizes SARS-CoV-2 and inhibits viral replication in vitro

Lessons learned 209 from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray 210 as medical device in children with acute symptoms of common cold

We would like to thank all members of the Department for Molecular and Medical Virology for 154 helpful suggestions and discussions. E.S was supported by the VIRus ALliance NRW